Essay 7 of 10 in the MU Plovdiv syllabus for Urology (Medicine, Year 4). The free AceMed note covers it in 5 sections, about 1,556 words (14 min of reading), with 15 flashcards.
In this note
In brief
Part A. Benign prostatic hyperplasia
Part B. Prostate carcinoma
Exam lens: USMLE / PLAB
References
In brief
Benign prostatic hyperplasia (BPH) is age-related growth of the transition zone that can obstruct the bladder outlet and cause lower urinary tract symptoms (LUTS); prostate cancer is a malignant tumour, usually an acinar adenocarcinoma of the peripheral zone, and the commonest cancer in men in Europe.
BPH is diagnosed from symptoms (IPSS), examination, urinalysis, flow rate and residual urine; prostate cancer from PSA and digital rectal examination, then MRI before biopsy, then targeted biopsy graded by ISUP grade group.
BPH: α1-blocker, add a 5α-reductase inhibitor for a large gland, surgery for complications or drug failure. Cancer: treatment follows the risk group, from active surveillance to radical therapy and, for metastases, androgen deprivation plus an androgen-receptor pathway inhibitor.
Part A. Benign prostatic hyperplasia
Definitions
BPH is a histological diagnosis (stromal and glandular proliferation); benign prostatic enlargement (BPE) is the enlarged gland; benign prostatic obstruction (BPO) is bladder outlet obstruction caused by BPE. LUTS are not specific to the prostate: bladder, kidney and nocturnal polyuria can all cause them.
Prevalence rises with age: histological BPH in about half of men at 60 and most by 80.
Pathogenesis
Arises in the transition zone around the urethra (cancer is mostly peripheral). Needs ageing and androgens: testosterone is converted to dihydrotestosterone (DHT) by 5α-reductase type 2, which drives stromal and epithelial nodules.
Static obstruction: bulk of the gland. Dynamic obstruction: tone of α1A-adrenergic smooth muscle in the stroma, capsule and bladder neck.
The bladder responds with detrusor hypertrophy, trabeculation and diverticula, then instability and finally decompensation with residual urine. BPH is not a premalignant lesion.
Risk of progression: age, prostate volume above 30–40 mL, PSA ≥1.5 ng/mL, high symptom score, low maximum flow rate (Qmax) and raised post-void residual (PVR).
Differential diagnosis of LUTS: overactive bladder, urethral stricture or bladder neck contracture, bladder cancer or stones, prostatitis, neurogenic bladder (diabetes, Parkinson disease, spinal disease), nocturnal polyuria, and drug effects (diuretics, anticholinergics, decongestants).
Assessment (EAU 2025)
International Prostate Symptom Score (IPSS): 0–7 mild, 8–19 moderate, 20–35 severe, plus the quality-of-life item. Frequency–volume chart (3 days) for nocturia and polyuria.
Examination with digital rectal examination (DRE: smooth, firm, enlarged gland); urinalysis; PSA if it will change management (life expectancy over 10 years, or to estimate volume and risk); creatinine if renal impairment is suspected.